Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 16434970 
Han YH, et al. (2006) Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene 25, 2974-86 16434970
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S473-p - Akt1 (human)
Orthologous residues
Akt1 (human): S473‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase

T202-p - ERK1 (human)
Orthologous residues
ERK1 (human): T202‑p, ERK1 (mouse): T203‑p, ERK1 (rat): T203‑p, ERK1 (hamster): T192‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 no change compared to control
SB203580 no change compared to control
JNK inhibitor I no change compared to control
anisomycin no change compared to control

Y204-p - ERK1 (human)
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 no change compared to control
SB203580 no change compared to control
JNK inhibitor I no change compared to control
anisomycin no change compared to control

T185-p - ERK2 (human)
Orthologous residues
ERK2 (human): T185‑p, ERK2 (mouse): T183‑p, ERK2 (rat): T183‑p, ERK2 (chicken): T193‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 no change compared to control
SB203580 no change compared to control
JNK inhibitor I no change compared to control
anisomycin no change compared to control

Y187-p - ERK2 (human)
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 no change compared to control
SB203580 no change compared to control
JNK inhibitor I no change compared to control
anisomycin no change compared to control

S63-p - Jun (human)
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 increase
SB203580 increase
JNK inhibitor I no change compared to control
anisomycin increase

S140-p - Nur77 (human)
Orthologous residues
Nur77 (human): S140‑p, Nur77 (mouse): S142‑p, Nur77 (rat): S139‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human

S351-p - Nur77 (human)
Orthologous residues
Nur77 (human): S351‑p, Nur77 (mouse): S354‑p, Nur77 (rat): S350‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) mutation in upstream enzyme recognition motif, transfection of constitutively active enzyme
Downstream Regulation
 Effect of modification (function):  phosphorylation
 Effect of modification (process):  apoptosis, induced, cytoskeletal reorganization
 Comments:  Akt inhibits MEKK1-mediated nuclear export of Nur77 by phosphorylating S351.

T180-p - P38A (human)
Orthologous residues
P38A (human): T180‑p, P38A iso2 (human): T180‑p, P38A (mouse): T180‑p, P38A iso3 (mouse): T180‑p, P38A (rat): T180‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 increase
SB203580 no change compared to control
JNK inhibitor I increase
anisomycin increase

Y182-p - P38A (human)
Orthologous residues
P38A (human): Y182‑p, P38A iso2 (human): Y182‑p, P38A (mouse): Y182‑p, P38A iso3 (mouse): Y182‑p, P38A (rat): Y182‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
PD98059 increase
SB203580 no change compared to control
JNK inhibitor I increase
anisomycin increase

T365-p - RSK2 (human)
Orthologous residues
RSK2 (human): T365‑p, RSK2 (mouse): T365‑p, RSK2 (rat): T365‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase

S369-p - RSK2 (human)
Orthologous residues
RSK2 (human): S369‑p, RSK2 (mouse): S369‑p, RSK2 (rat): S369‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Disease tissue studied:  lung cancer, non-small cell lung cancer
 Relevant cell lines - cell types - tissues:  293 (epithelial), NCI-H460 (pulmonary)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
phorbol ester increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.